The real impact of COVID‐19 on an East London Sickle cell population: results of a service‐wide survey

Hall, Rhys; Meenan, John; Mihalca, Diana; Katumba, Alvin; Badle, Saket; Osakonor, Dede-Kossi; Bello-Sanyaolu, Oloruntoyin; Orebayo, Funmilayo; Lewis, Natasha; Chatterjee, Basabi; Coughlin, S.P.; Tsitsikas, Dimitris A.

doi:10.1111/bjh.17740

Cited by 3 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 However, a study of a population of patients with SCD in London found that vaccination uptake was around 80%, higher than among older people of African origin in general. 17 These safety results for COVID-19 vaccines are reassuring and might help to promote vaccination among reluctant patients at a high risk of COVID-19.…”

Section: Discussionmentioning

confidence: 90%

“…Studies in many countries have shown that the socio‐professional category, ethnicity, geographical origin and political affiliations can influence the level of vaccination 16 . However, a study of a population of patients with SCD in London found that vaccination uptake was around 80%, higher than among older people of African origin in general 17 …”

Section: Discussionmentioning

confidence: 99%

“… 16 However, a study of a population of patients with SCD in London found that vaccination uptake was around 80%, higher than among older people of African origin in general. 17 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease

et al. 2022

View full text Add to dashboard Cite

Summary Given the lack of information about safety of the COVID‐19 vaccines for sickle cell disease (SCD) patients, we sought to determine whether COVID‐19 vaccine was associated with subsequent hospital admission for vaso‐occlusive events (VOEs). We included 402 patients with SCD, including 88 regularly transfused. As of July 31, 2021, 213 (53.0%) of them had received a least one dose of COVID vaccine (Pfizer 93.0%). We showed similar risk of hospital admission for a VOE among vaccinated patients (whether transfused or not) and among a control group of non‐vaccinated patients matched for age, sex and genotype.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Finally, some studies suggest that when it comes to COVID-19, individuals with sickle cell disease or sickle cell trait have similar rates of death, hospitalization, and ICU admission compared to people without sickle cell disease or sickle cell trait ( 31 , 34 , 42 , 47 , 49 , 58 , 70 , 80 , 85 , 87 , 108 ). These papers did not identify mechanisms related to sickle cell disease that act directly in the clinical course of COVID-19 but instead highlighted features also observed in the general population, such as the existence of other comorbidities, advanced age, and the presence of organ damage, as risk factors for unfavorable outcomes ( 57 , 59 ).…”

Section: Discussionmentioning

confidence: 99%

“…Vaccination, an essential tool for reducing mortality from infectious causes in this population, should also be encouraged in all age groups, as it has been for the general population ( 2 , 47 , 106 ). Studies show that there may be some hesitation among people with sickle cell disease regarding the safety profile of immunizers against SARS-CoV-2 and the occurrence of adverse effects ( 121 ).…”

Section: Discussionmentioning

confidence: 99%

Impact of the SARS-CoV-2 infection in individuals with sickle cell disease: an integrative review

et al. 2023

View full text Add to dashboard Cite

Sickle cell disease is the most common hemoglobinopathy among humans. As the condition promotes susceptibility to infections, chronic inflammation, and hypercoagulability disorders, several international agencies have included individuals with this disease in the COVID-19 risk group for severe outcomes. However, available information about the subject is not properly systematized yet. This review aimed to understand and summarize the scientific knowledge about the impact of SARS-CoV-2 infection in patients with sickle cell disease. Searches were performed in the Medline, PubMed, and Virtual Health Library databases based on descriptors chosen according to the Medical Subject Headings. We analyzed studies published between 2020 and October 2022, developed with qualitative, quantitative, or mixed methodology, and written in English, Spanish, or Portuguese. The search resulted in 90 articles organized into six categories. There is disagreement in the literature about how different aspects related to sickle cell disease, such as chronic inflammation status, hypercoagulability, hemolytic anemia, use of hydroxyurea, and access to medical care interference with the clinical course of COVID-19. These topics deserve further investigation. It is evident, however, that the infection may manifest in an atypical way and act as a trigger for the development of sickle cell-specific complications, such as acute chest syndrome and vaso-occlusive crises, conditions that are associated with great morbidity and mortality. Therefore, healthcare professionals must be aware of the different forms of presentation of COVID-19 among these individuals. Specific guidelines and therapeutic protocols, as well as public policies for sickle cell individuals, must be considered.Systematic review registrationThis review (https://doi.org/10.17605/OSF.IO/NH4AS) and the review protocol (https://osf.io/3y649/) are registered in the Open Science Framework platform.

show abstract

Presentations and outcomes among sickle cell disease patients with COVID-19 at a large southern healthcare system

Clarke

Shin

Hall

et al. 2022

Expert Review of Hematology

View full text Add to dashboard Cite

The real impact of COVID‐19 on an East London Sickle cell population: results of a service‐wide survey

Abstract: Fig 1. Distribution of answers according to genotype (A), age (B) and gender (C). Vaccination Y/NY, vaccinated already/keen to be vaccinated but not yet received first dose; Vaccination U, uncertain whether to be vaccinated; Vaccination DW, does not want to be vaccinated.

Cited by 3 publications

References 7 publications

Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease

Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease

Impact of the SARS-CoV-2 infection in individuals with sickle cell disease: an integrative review

Presentations and outcomes among sickle cell disease patients with COVID-19 at a large southern healthcare system

Contact Info

Product

Resources

About